oxazoles has been researched along with camptothecin in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 4 (57.14) | 2.80 |
| Authors | Studies |
|---|---|
| Barthel, B; Koch, TH; Shi, D; Xiao, D; Yan, B; Yang, D | 1 |
| Charpentier, M; Guo, L; Lu, W; Xiao, D; Yan, B; Yang, D | 1 |
| Alexander, C; Ashford, MB; Barnes, J; Barry, ST; England, RM; Hare, JI; Kemmitt, PD; Smith, A; Strittmatter, N; Waring, MJ; Wilson, J | 1 |
| Rugo, HS | 1 |
| Gelmon, KA; Tesch, ME | 1 |
| Cardoso, F; Cortes, J; Curigliano, G; Prat, A; Tarantino, P | 1 |
| Exman, P; Tolaney, SM | 1 |
3 review(s) available for oxazoles and camptothecin
| Article | Year |
|---|---|
Targeting HER2 in Breast Cancer: Latest Developments on Treatment Sequencing and the Introduction of Biosimilars.
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biosimilar Pharmaceuticals; Breast; Breast Neoplasms; Camptothecin; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Disease-Free Survival; Female; Humans; Immunoconjugates; Lapatinib; Mastectomy; Maytansine; Medical Oncology; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Oxazoles; Practice Guidelines as Topic; Pyridines; Quinazolines; Quinolines; Receptor, ErbB-2; Trastuzumab | 2020 |
Third-line treatment of HER2-positive advanced breast cancer: From no standard to a Pandora's box.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Female; Humans; Immunoconjugates; Kaplan-Meier Estimate; Oxazoles; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Trastuzumab | 2021 |
HER2-positive metastatic breast cancer: a comprehensive review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Bridged-Ring Compounds; Camptothecin; Female; Humans; Immunoconjugates; Neoplasm Metastasis; Oxazoles; Pyridines; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab | 2021 |
4 other study(ies) available for oxazoles and camptothecin
| Article | Year |
|---|---|
Carboxylesterase-2 is a highly sensitive target of the antiobesity agent orlistat with profound implications in the activation of anticancer prodrugs.
Topics: Animals; Anti-Obesity Agents; Antineoplastic Agents; Camptothecin; Carboxylic Ester Hydrolases; Cell Line; Cell Survival; Doxorubicin; Drug Interactions; Female; Humans; Irinotecan; Lactones; Liver; Male; Mice; Orlistat; Oxazoles; Prodrugs; Rats; Species Specificity | 2013 |
Regulation of carboxylesterase-2 expression by p53 family proteins and enhanced anti-cancer activities among 5-fluorouracil, irinotecan and doxazolidine prodrug.
Topics: Animals; Antineoplastic Agents; Caco-2 Cells; Camptothecin; Carboxylesterase; Carboxylic Ester Hydrolases; Cell Line, Tumor; Doxorubicin; Fluorouracil; Gene Expression Regulation, Neoplastic; Hep G2 Cells; HT29 Cells; Humans; Irinotecan; Mice; Oxazoles; RNA Stability; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2013 |
Tumour regression and improved gastrointestinal tolerability from controlled release of SN-38 from novel polyoxazoline-modified dendrimers.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Colon; Colorectal Neoplasms; Delayed-Action Preparations; Dendrimers; Female; Irinotecan; Mice; Mice, Nude; Oxazoles; Rats, Wistar; Rectum | 2017 |
Highlights from the 2019 San Antonio Breast Cancer Symposium.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast; Breast Neoplasms; Camptothecin; Clinical Trials as Topic; Female; Humans; Immunoconjugates; Oxazoles; Paclitaxel; Prognosis; Pyridines; Quinazolines; Texas; Trastuzumab | 2020 |